Evidence map›Paper›PMID 29976841›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Personalized disease signatures through information-theoretic compaction of big cancer data.

Swetha Vasudevan, Efrat Flashner-Abramson, F Remacle, R D Levine, Nataly Kravchenko-Balasha

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Overcoming resistance to BRAFNPJ precision oncology · 2021
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Swetha VasudevanBio-Medical Sciences Department, The Faculty of Dental Medicine, The Hebrew University of Jerusalem, 9112001 Jerusalem, Israel.
Efrat Flashner-AbramsonBio-Medical Sciences Department, The Faculty of Dental Medicine, The Hebrew University of Jerusalem, 9112001 Jerusalem, Israel.
F RemacleFritz Haber Research Centre, Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel.
R D LevineFritz Haber Research Centre, Institute of Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel; rafi@fh.huji.ac.il natalyk@ekmd.huji.ac.il.
Nataly Kravchenko-BalashaBio-Medical Sciences Department, The Faculty of Dental Medicine, The Hebrew University of Jerusalem, 9112001 Jerusalem, Israel; rafi@fh.huji.ac.il natalyk@ekmd.huji.ac.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Every individual cancer develops and grows in its own specific way, giving rise to a recognized need for the development of personalized cancer diagnostics. This suggested that the identification of patient-specific oncogene markers would be an effective diagnostics approach. However, tumors that are classified as similar according to the expression levels of certain oncogenes can eventually demonstrate divergent responses to treatment. This implies that the information gained from the identification of tumor-specific biomarkers is still not sufficient. We present a method to quantitatively transform heterogeneous big cancer data to patient-specific transcription networks. These networks characterize the unbalanced molecular processes that deviate the tissue from the normal state. We study a number of datasets spanning five different cancer types, aiming to capture the extensive interpatient heterogeneity that exists within a specific cancer type as well as between cancers of different origins. We show that a relatively small number of altered molecular processes suffices to accurately characterize over 500 tumors, showing extreme compaction of the data. Every patient is characterized by a small specific subset of unbalanced processes. We validate the result by verifying that the processes identified characterize other cancer patients as well. We show that different patients may display similar oncogene expression levels, albeit carrying biologically distinct tumors that harbor different sets of unbalanced molecular processes. Thus, tumors may be inaccurately classified and addressed as similar. These findings highlight the need to expand the notion of tumor-specific oncogenic biomarkers to patient-specific, comprehensive transcriptional networks for improved patient-tailored diagnostics.

Indexed as

Databases, GeneticGene Expression Regulation, NeoplasticGene Regulatory NetworksNeoplasmsPatient-Specific ModelingTranscriptomeHumanscancer diagnosticsinformation theoryintertumor heterogeneitypatient-specific gene expression signaturessurprisal analysis

Identifiers

PMID29976841
PMCPMC6065026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.